Literature DB >> 30864392

Enhancing the anticoagulant profile of meizothrombin.

Bosko M Stojanovski1, Leslie A Pelc1, Xiaobing Zuo2, Nicola Pozzi1, Enrico Di Cera1.   

Abstract

Meizothrombin is an active intermediate generated during the proteolytic activation of prothrombin to thrombin in the penultimate step of the coagulation cascade. Structurally, meizothrombin differs from thrombin because it retains the auxiliary Gla domain and two kringles. Functionally, meizothrombin shares with thrombin the ability to cleave procoagulant (fibrinogen), prothrombotic (PAR1) and anticoagulant (protein C) substrates, although its specificity toward fibrinogen and PAR1 is less pronounced. In this study we report information on the structural architecture of meizothrombin resolved by SAXS and single molecule FRET as an elongated arrangement of its individual domains. In addition, we show the properties of a meizothrombin construct analogous to the anticoagulant thrombin mutant W215A/E217A currently in Phase I for the treatment of thrombotic complications and stroke. The findings reveal new structural and functional aspects of meizothrombin that advance our understanding of a key intermediate of the prothrombin activation pathway.

Entities:  

Keywords:  Enzyme Specificity; Protein Engineering; Thrombin

Mesh:

Substances:

Year:  2018        PMID: 30864392      PMCID: PMC6825329          DOI: 10.1515/bmc-2018-0016

Source DB:  PubMed          Journal:  Biomol Concepts        ISSN: 1868-5021


  42 in total

Review 1.  The transition of prothrombin to thrombin.

Authors:  S Krishnaswamy
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Calcium ion modulation of meizothrombin autolysis at Arg55-Asp56 and catalytic activity.

Authors:  W K Stevens; H F Côté; R T MacGillivray; M E Nesheim
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

3.  Autocatalytic peptide bond cleavages in prothrombin and meizothrombin.

Authors:  R J Petrovan; J W Govers-Riemslag; G Nowak; H C Hemker; G Tans; J Rosing
Journal:  Biochemistry       Date:  1998-02-03       Impact factor: 3.162

4.  Engineering thrombin for selective specificity toward protein C and PAR1.

Authors:  Francesca Marino; Leslie A Pelc; Austin Vogt; Prafull S Gandhi; Enrico Di Cera
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

5.  Na+ binding to meizothrombin desF1.

Authors:  M E Papaconstantinou; P S Gandhi; Z Chen; A Bah; E Di Cera
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

6.  The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.

Authors:  Agustin O Pineda; Zhi-Wei Chen; Sonia Caccia; Angelene M Cantwell; Savvas N Savvides; Gabriel Waksman; F Scott Mathews; Enrico Di Cera
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

7.  Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma.

Authors:  G Tans; T Janssen-Claessen; H C Hemker; R F Zwaal; J Rosing
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

8.  Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process.

Authors:  Nicole Brufatto; Michael E Nesheim
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

9.  How the Linker Connecting the Two Kringles Influences Activation and Conformational Plasticity of Prothrombin.

Authors:  Nicola Pozzi; Zhiwei Chen; Enrico Di Cera
Journal:  J Biol Chem       Date:  2016-01-12       Impact factor: 5.157

10.  Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation.

Authors:  J Rosing; R F Zwaal; G Tans
Journal:  J Biol Chem       Date:  1986-03-25       Impact factor: 5.157

View more
  4 in total

1.  Cryo-EM structure of the prothrombin-prothrombinase complex.

Authors:  Eliza A Ruben; Brock Summers; Michael J Rau; James A J Fitzpatrick; Enrico Di Cera
Journal:  Blood       Date:  2022-06-16       Impact factor: 25.476

2.  Zymogen and activated protein C have similar structural architecture.

Authors:  Bosko M Stojanovski; Leslie A Pelc; Xiaobing Zuo; Enrico Di Cera
Journal:  J Biol Chem       Date:  2020-08-27       Impact factor: 5.157

3.  Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.

Authors:  Jean-Paul Motta; Simone Palese; Carmine Giorgio; Kevin Chapman; Alexandre Denadai-Souza; Perrine Rousset; David Sagnat; Laura Guiraud; Anissa Edir; Carine Seguy; Laurent Alric; Delphine Bonnet; Barbara Bournet; Louis Buscail; Cyrielle Gilletta; Andre G Buret; John L Wallace; Morley D Hollenberg; Eric Oswald; Elisabetta Barocelli; Sylvie Le Grand; Bruno Le Grand; Celine Deraison; Nathalie Vergnolle
Journal:  J Crohns Colitis       Date:  2021-05-04       Impact factor: 9.071

4.  Screening of the Promising Direct Thrombin Inhibitors from Haematophagous Organisms. Part I: Recombinant Analogues and Their Antithrombotic Activity In Vitro.

Authors:  Maria A Kostromina; Elena A Tukhovskaya; Elvira R Shaykhutdinova; Gulsara A Slashcheva; Alina M Ismailova; Victor A Palikov; Yuliya A Palikova; Igor A Dyachenko; Irina N Kravchenko; Elena S Sadovnikova; Nadezhda I Novikova; Natalia A Perepechenova; Evgeniy A Zayats; Yuliya A Abramchik; Dmitry D Lykoshin; Andrey N Mamaev; Elena V Grigorieva; Andrey P Momot; Arkady N Murashev; Roman S Esipov
Journal:  Biomedicines       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.